Multiparametric MRI radiomics for noninvasive prediction of HER2 status in immunohistochemical 2+ breast cancer.

ABSTRACT:

Background

Breast cancer (BC) patients with low expression of human epidermal growth factor receptor 2 (HER2), now classified as HER2-low, may benefit from new novel antibody-drug conjugates, such as trastuzumab deruxtecan. However, patients with immunohistochemistry (IHC) 2+ require further fluorescence in situ hybridization (FISH) to definitively determine HER2 status. Our study aims to explore the feasibility of radiomics models based on multiparametric magnetic resonance imaging (mpMRI) in predicting the HER2 status of IHC 2+ BC patients.

Materials and methods

107 IHC 2+ BC patients, which composed of 65 (60.75%) FISH-negative and 42 (39.25%) FISH-positive, were enrolled in the retrospective study and divided into the training set (n = 74) and testing set (n = 33)

SUBMITTER: Li X 

PROVIDER: S-EPMC12846950 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature